



Dectrovir-N™

Composition:

Lamivudine	150 mg
Zidovudine USP	300 mg
Nevirapine	200 mg

Indications:

Dectrovir-N is indicated for the treatment of HIV infection, once patients have been stabilized on the maintenance regimen of nevirapine 200 mg bd, and have demonstrated adequate tolerability to nevirapine.

Description:

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time.

Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.

Side Effects

In controlled clinical trials, the most common Nevirapine side effect was rash, which in 7.6% of subjects was considered severe. Increases in the liver enzymes occurred in 5-10% of subjects compared with 2-5% in controls.

CONTRAINDICATIONS:

Nevirapine is contraindicated in patients with clinically significant hypersensitivity to any of the components contained in the tablet or the oral suspension.

Drug Interaction

Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A4 and 2B6. Nevirapine is known to be an inducer of these enzymes. As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when coadministered with nevirapine.

Dosage: Adults: 1 tablet twice daily or as per the physician's advice.

Presentations:	30 tablets		
	MRP	Retailer	Stockist
	675.00	540.00	486.00